// STATE LEGISLATION TRACKER

Hawaii SB 2421: RELATING TO CANNABIS.

⚖️ NEUTRAL for peptide users 👤 NONE user impact 📜 Status: Unknown

State: Hawaii
Bill: SB 2421
Session: 2026
Filed: 2026-01-20
Read the bill: OpenStates →
Last reviewed: 2026-10-05

Plain-English Summary

Hawaii SB2421 appears to be a cannabis and hemp bill, not a peptide, prescription drug, compounding, or clinician-scope bill. Based on the title, subjects, and pending-introduction status, it has no clear direct effect on compounded peptides, off-label peptide prescribing, telehealth peptide care, NP/naturopath scope, FDA 503A/503B compounding, controlled substances, or PDMP rules.

Key Points

No apparent change to compounded peptide access or pharmacy rules
No apparent change to off-label prescribing for peptides
No apparent change to telehealth peptide prescribing
No apparent change to NP or naturopath peptide scope
Watch only if later text adds pharmacy or prescribing provisions

What to Watch For

Note Bill appears focused on cannabis and hemp regulation, not peptide medicines or compounding.

Note If amended, check for any pharmacy, prescribing, telehealth, or controlled-substance language.

Note Pending-introduction status means the bill text or impact could change before committee review.

Where the Bill Stands

The listed latest action is Pending Introduction, so the bill does not appear to have clearly advanced into committee yet.

· Ed. Our analysis pulls public bill metadata from OpenStates and is enriched with research-model context. We don't quote bill text we haven't read directly. If this bill matters to your practice or treatment access, read the official source linked above before taking action. We're an educational research directory, not a legal or medical reference.

Bill page generated 2026-11-04 · enriched via codex gpt-5.5
Source: OpenStates v3 API · View official bill · ← back to all laws